Fortis Healthcare has provided a mandatory disclosure regarding an ongoing material litigation involving its promoter shareholder, Northern TK Venture Pte Ltd. (NTK), against Daiichi Sankyo in the Tokyo District Court, Japan. NTK has filed a Petition to Amend Claims, focusing on amending injunctive relief sought to prevent future obstruction of the acquisition of Fortis and Malar shares. There is no change to the quantum of damages previously sought.
Disclosure on Promoter Shareholder Litigation
Fortis Healthcare Limited announced an update concerning the material litigation filed by its promoter shareholder, Northern TK Venture Pte Ltd. (“NTK”), against Daiichi Sankyo Company Limited before the Tokyo District Court in Japan. This disclosure is made in furtherance of previous announcements regarding this matter.
Latest Court Filings
The Board of Directors of IHH Healthcare, the parent company of NTK, announced that on 12 February 2026, NTK submitted a “Petition to Amend Claims” to the Court. This petition was delivered to Daiichi Sankyo on 17 February 2026. The event occurrence date for this disclosure is noted as February 19, 2026, at 1506 hours.
Background on Relief Sought
The litigation, originally announced in November 2023 and updated in May 2025, originally sought significant reliefs, including:
-
Monetary damages against Daiichi Sankyo, including an amount equivalent to JPY199,785,395,700.48 for tortious claims and JPY5,000,000 for defamation claims, plus accrued interest.
-
An injunction to restrain Daiichi Sankyo from making defamatory statements to the Security and Exchanges Board of India (“SEBI”) and other third parties, described as the “Injunctive Claim.”
-
A directive for Daiichi Sankyo to publish a vindication statement on its website and issue one to SEBI.
Amendments Post-Transaction Completion
Following the completion of the Open Offers on 10 November 2025, the Petition to Amend Claims specifically seeks to modify the Injunctive Claim. The amendment aims to prevent Daiichi Sankyo from obstructing the acquisition of shares and other corporate exercises concerning Fortis and Malar by NTK, specifically through defamatory statements made to SEBI or the public. Crucially, there is no reported change to the other reliefs sought by NTK, including the damages amount, although NTK has reserved its rights to further amend the damages amount later.
Next Steps
Fortis Healthcare confirms it will inform the public in case of any further material developments concerning this litigation.
Source: BSE
